PDGFRA and melanoma: We and others have demonstrated that mutations, increased copy numbers, and overexpression of PDGFRA occur in melanoma patients, and that functional mutations of PDGFRA increase MAPK and PI3K/AKT pathway activation, which can be inhibited by several tyrosine kinase inhibitors such as imatinib, crenolanib, and sunitinib 6-8.